References
- RothTInsomnia: definition, prevalence, etiology, and consequencesJ Clin Sleep Med200735 supplS7S1017824495
- SateiaMJInternational classification of sleep disorders-third editionChest201414651387139425367475
- Merck & Co IncBelsomra [Package Insert]Whitehouse, NJMerck & Co., Inc2014
- KrystalADBencaRMKilduffTSUnderstanding the sleep-wake cycle: sleep, insomnia, and the orexin systemJ Clin Psychiatry201374suppl 132024107804
- UslanerJMRengerJJColemanPJWinrowCJA new class of hypnotic compounds for the treatment of insomnia: the dual orexin receptor antagonistsOrexin and SleepSakuraiTPandi-PerumalSRMontiJMChamSpringer International Publishing2015323338
- JacobsonLHCallanderGEHoyerDSuvorexant for the treatment of insomniaExpert Rev Clin Pharmacol20147671173025318834
- SnyderEMaJSvetnikVEffects of suvorexant on sleep architecture and power spectral profile in patients with insomnia: analysis of pooled phase 3 dataSleep Med2016199310027198953
- GotterALWinrowCJBrunnerJThe duration of sleep promoting efficacy by dual orexin receptor antagonists is dependent upon receptor occupancy thresholdBMC Neurosci20131419023981345
- SunHKennedyWPWilbrahamDEffects of suvorexant, an orexin receptor antagonist, on sleep parameters as measured by polysomnography in healthy menSleep201336225926723372274
- HerringWJSnyderEBuddKOrexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexantNeurology201279232265227423197752
- HerringWJConnorKMIvgy-MayNSuvorexant in patients with insomnia: results from two 3-month randomized controlled clinical trialsBiol Psychiatry201679213614825526970
- MichelsonDSnyderEParadisESafety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trialLancet Neurol201413546147124680372
- RoehrsTARandallSHarrisEMaanRRothTTwelve months of nightly zolpidem does not lead to rebound insomnia or withdrawal symptoms: a prospective placebo-controlled studyJ Psychopharmacol20122681088109522004689
- KishiTMatsunagaSIwataNSuvorexant for primary insomnia: a systematic review and meta-analysis of randomized placebo-controlled trialsPLoS One2015108e013691026317363
- CitromeLSuvorexant for insomnia: a systematic review of the efficacy and safety profile for this newly approved hypnotic – what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?Int J Clin Pract201468121429144125231363
- GlassJLanctôtKLHerrmannNSprouleBABustoUESedative hypnotics in older people with insomnia: meta-analysis of risks and benefitsBMJ20053317526116916284208
- McMillanJMAitkenEHolroyd-LeducJMManagement of insomnia and long-term use of sedative-hypnotic drugs in older patientsCMAJ2013185171499150524062170
- SunHPalczaJCardDEffects of suvorexant, an orexin receptor antagonist, on respiration during sleep in patients with obstructive sleep apneaJ Clin Sleep Med201612191726194728
- SunHYeeKLGillSPsychomotor effects, pharmacokinetics and safety of the orexin receptor antagonist suvorexant administered in combination with alcohol in healthy subjectsJ Psychopharmacol201529111159116926464455
- CuiDCabaluTYeeKLIn vitro and in vivo characterisation of the metabolism and disposition of suvorexant in humansXenobiotica20164611426068521
- SchoedelKASunHSellersEMAssessment of the abuse potential of the orexin receptor antagonist, suvorexant, compared with zolpidem in a randomized crossover studyJ Clin Psychopharmacol Epub2016531
- KuriyamaAHondaMHayashinoYRamelteon for the treatment of insomnia in adults: a systematic review and meta-analysisSleep Med201415438539224656909
- WinklerAAuerCDoeringBKRiefWDrug treatment of primary insomnia: a meta-analysis of polysomnographic randomized controlled trialsCNS Drugs201428979981625168785
- MaJSvetnikVSnyderELinesCRothTHerringWJElectroencephalographic power spectral density profile of the orexin receptor antagonist suvorexant in patients with primary insomnia and healthy subjectsSleep201437101609161925197807